Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q06124: Variant p.Gly464Ala

Tyrosine-protein phosphatase non-receptor type 11
Gene: PTPN11
Feedback?
Variant information Variant position: help 464 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Alanine (A) at position 464 (G464A, p.Gly464Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LPRD1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 464 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 593 The length of the canonical sequence.
Location on the sequence: help HKQESIMDAGPVVVHCSAGI G RTGTFIVIDILIDIIREKGV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGV

Mouse                         HKQESIVDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGV

Rat                           HKQESIVDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGV

Chicken                       HKQESISDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGV
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 593 Tyrosine-protein phosphatase non-receptor type 11
Domain 247 – 517 Tyrosine-protein phosphatase
Active site 459 – 459 Phosphocysteine intermediate
Binding site 459 – 465
Alternative sequence 460 – 460 S -> R. In isoform 3.
Alternative sequence 461 – 593 Missing. In isoform 3.
Mutagenesis 459 – 459 C -> S. Abolishes phosphatase activity. Enhances interaction with NEDD9.
Helix 464 – 482



Literature citations
Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome.
Yoshida R.; Nagai T.; Hasegawa T.; Kinoshita E.; Tanaka T.; Ogata T.;
Am. J. Med. Genet. A 130:432-434(2004)
Cited for: VARIANTS LPRD1 THR-461 AND ALA-464; Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome.
Sarkozy A.; Conti E.; Digilio M.C.; Marino B.; Morini E.; Pacileo G.; Wilson M.; Calabro R.; Pizzuti A.; Dallapiccola B.;
J. Med. Genet. 41:E68-E68(2004)
Cited for: VARIANTS LPRD1 CYS-279; SER-279; ALA-464; MET-468; TRP-498; LEU-498 AND PRO-506;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.